Bright Minds Biosciences (DRUG) to Release Earnings on Friday

Key Points

• Q2 2026 results: Bright Minds will report before market open on May 15, 2026; analysts expect EPS of ($0.924), with consensus forecasts of about -$5 for the current fiscal year and -$8 for the next.
• Market and analyst view: Shares opened near $88.82 (52‑week range $23.17–$123.75) and the stock has an average rating of "Moderate Buy" from analysts with an average price target of $128.60 (six Buys, one Hold).
• Insider and institutional activity: Major shareholder Cormorant sold 109,331 shares for about $9.79M, reducing its stake by 10.32%, while institutional ownership is roughly 40.5% and some funds (e.g., Millennium) markedly increased positions.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) is expected to release its Q2 2026 results before the market opens on Friday, May 15th. Analysts expect Bright Minds Biosciences to post earnings of ($0.9240) per share for the quarter. Interested persons may visit the the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.98) by $0.28. On average, analysts expect Bright Minds Biosciences to post $-5 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Bright Minds Biosciences Stock Down 0.1%

Shares of NASDAQ:DRUG opened at $88.82 on Friday. Bright Minds Biosciences has a 52-week low of $23.17 and a 52-week high of $123.75. The stock has a market cap of $864.22 million, a P/E ratio of -46.02 and a beta of -5.35. The business has a fifty day moving average of $80.53 and a two-hundred day moving average of $76.99.

Analyst Ratings Changes

A number of research firms recently commented on DRUG. Jefferies Financial Group initiated coverage on Bright Minds Biosciences in a report on Monday, April 13th. They issued a "buy" rating and a $145.00 price objective on the stock. BTIG Research reissued a "buy" rating and set a $147.00 target price on shares of Bright Minds Biosciences in a research note on Monday, March 30th. HC Wainwright raised their target price on Bright Minds Biosciences from $115.00 to $145.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Robert W. Baird set a $126.00 price target on shares of Bright Minds Biosciences in a research note on Friday, February 13th. Finally, Wall Street Zen lowered shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, April 18th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $128.60.

Insider Activity

In related news, major shareholder Cormorant Asset Management, Lp sold 109,331 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $89.50, for a total value of $9,785,124.50. Following the transaction, the insider owned 950,000 shares of the company's stock, valued at $85,025,000. This represents a 10.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 42.66% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DRUG. Millennium Management LLC lifted its position in Bright Minds Biosciences by 376.9% in the first quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after acquiring an additional 152,178 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Bright Minds Biosciences during the first quarter worth about $802,000. Geode Capital Management LLC acquired a new stake in shares of Bright Minds Biosciences during the second quarter worth about $1,502,000. JPMorgan Chase & Co. lifted its holdings in shares of Bright Minds Biosciences by 624.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company's stock valued at $57,000 after purchasing an additional 1,873 shares during the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in shares of Bright Minds Biosciences in the 2nd quarter valued at about $107,000. 40.52% of the stock is owned by institutional investors and hedge funds.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.